<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564833</url>
  </required_header>
  <id_info>
    <org_study_id>REN-004</org_study_id>
    <nct_id>NCT04564833</nct_id>
  </id_info>
  <brief_title>Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery</brief_title>
  <acronym>START</acronym>
  <official_title>A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing Coronary Artery Bypass Graft (CABG) and/or Cardiac Valve Surgery (The START Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renibus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Renibus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of RBT-1 (stannous protoporphyrin&#xD;
      [SnPP]/iron sucrose [FeS]) on preconditioning response biomarkers in subjects who are at risk&#xD;
      for AKI following cardiac surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized 1:1:1 to low dose RBT-1, high dose RBT-1, and placebo</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of RBT-1 in generating a preconditioning response as measured by a composite of biomarkers</measure>
    <time_frame>Baseline through Day 3 post-dose</time_frame>
    <description>Plasma heme oxygenase-1 (HO-1), ferritin, and interleukin-10 (IL-10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in renal tubular injury biomarkers</measure>
    <time_frame>Baseline through Day 3 post-cardiac surgery</time_frame>
    <description>KIM-1, NGAL, cystatin C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in urine output</measure>
    <time_frame>Baseline through Day 3 post-cardiac surgery</time_frame>
    <description>Documented oliguria of &lt;0.5 mL/kg/hour for more than 6 hours post-cardiac surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute kidney injury (AKI)</measure>
    <time_frame>Baseline through Day 5 post-cardiac surgery</time_frame>
    <description>AKI is defined using the KDIGO criteria (ie, an absolute increase in serum creatinine by 0.5 mg/dL, which is present over 2 laboratory measurements at least 12 hours apart; or an increase in serum creatinine ≥1.5 × Baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>AKI</condition>
  <arm_group>
    <arm_group_label>Low Dose RBT-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 mg SnPP/240 mg FeS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose RBT-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 mg SnPP/240 mg FeS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose RBT-1</intervention_name>
    <description>45 mg SnPP/240 mg FeS will be administered as a single IV infusion over a 120-minute period ≥24 hours but ≤48 hours prior to scheduled cardiac surgery</description>
    <arm_group_label>Low Dose RBT-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose RBT-1</intervention_name>
    <description>Normal saline will be administered as a single IV infusion over a 120-minute period ≥24 hours but ≤48 hours prior to scheduled cardiac surgery</description>
    <arm_group_label>High Dose RBT-1</arm_group_label>
    <other_name>90 mg SnPP/240 mg FeS will be administered as a single IV infusion over a 120-minute period ≥24 hours but ≤48 hours prior to scheduled cardiac surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline will be administered as a single IV infusion over a 120-minute period ≥24 hours but ≤48 hours prior to scheduled cardiac surgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects ≥18 years of age at Screening.&#xD;
&#xD;
          2. Able and willing to comply with all study procedures.&#xD;
&#xD;
          3. Stable kidney function per Investigator assessment and no known episodes of AKI during&#xD;
             the preceding 4 weeks.&#xD;
&#xD;
          4. Scheduled to undergo non-emergent coronary and/or valve surgery(ies) requiring&#xD;
             cardiopulmonary bypass, including:&#xD;
&#xD;
               -  CABG alone;&#xD;
&#xD;
               -  Combined CABG surgery/repair of 1 or more cardiac valves;&#xD;
&#xD;
               -  Cardiac valve(s) replacement or repair alone.&#xD;
&#xD;
          5. Females and males of childbearing potential must agree to use 2 forms of&#xD;
             contraception, with at least 1 being a barrier method, or abstain from sexual activity&#xD;
             for 30 days following study drug administration.&#xD;
&#xD;
          6. Male subjects must agree not to donate or sell sperm for 30 days following study drug&#xD;
             administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of AKI (KDIGO criteria) at the time of Screening.&#xD;
&#xD;
          2. Surgery to be performed without cardiopulmonary bypass.&#xD;
&#xD;
          3. Surgery to be performed under conditions of circulatory arrest or hypothermia with&#xD;
             rectal temperature &lt;28°C (82.4°F).&#xD;
&#xD;
          4. eGFR ≤20 mL/min/1.73m2 or need for dialysis.&#xD;
&#xD;
          5. Surgery for aortic dissection or to correct a major congenital heart defect.&#xD;
&#xD;
          6. Administration of iodinated contrast media within 24 hours prior to cardiac surgery or&#xD;
             evidence of contrast-induced nephropathy prior to cardiac surgery.&#xD;
&#xD;
          7. Cardiogenic shock or hemodynamic instability within the 24 hours prior to surgery and&#xD;
             requirement for inotropes or vasopressors or other mechanical devices, such as&#xD;
             intra-aortic balloon counter-pulsation.&#xD;
&#xD;
          8. Requirement for any of the following within 7 days prior to cardiac surgery:&#xD;
&#xD;
               -  Defibrillator or permanent pacemaker;&#xD;
&#xD;
               -  Mechanical ventilation;&#xD;
&#xD;
               -  Intra-aortic balloon counter-pulsation;&#xD;
&#xD;
               -  Left ventricular assist device;&#xD;
&#xD;
               -  Other forms of mechanical circulatory support.&#xD;
&#xD;
          9. Known history of cancer within the past 2 years, except for carcinoma in situ of the&#xD;
             cervix or adequately treated basal cell carcinoma of the skin.&#xD;
&#xD;
         10. Known or suspected sepsis at time of Screening or confirmed or treated endocarditis&#xD;
             within 30 days prior to cardiac surgery.&#xD;
&#xD;
         11. Other current active infection requiring systemic antibiotic treatment.&#xD;
&#xD;
         12. Inadequate hepatic function, defined as total bilirubin or alanine aminotransferase or&#xD;
             aspartate aminotransferase &gt;2X the upper limit of normal at time of Screening or Child&#xD;
             Pugh Class C liver disease or higher.&#xD;
&#xD;
         13. Any congenital coagulation disorder.&#xD;
&#xD;
         14. Asplenia (anatomic or functional).&#xD;
&#xD;
         15. History of photosensitivity or active skin disease that, in the opinion of the&#xD;
             Investigator, could be worsened by RBT-1.&#xD;
&#xD;
         16. Known hypersensitivity or previous anaphylaxis to SnPP or any tin-based product.&#xD;
&#xD;
         17. Serum ferritin &gt;500 ng/mL or those who have received IV iron within 28 days of&#xD;
             Screening.&#xD;
&#xD;
         18. Pregnancy or lactation.&#xD;
&#xD;
         19. Treatment with an investigational drug or participation in an interventional study&#xD;
             within 30 days prior to administration of study drug.&#xD;
&#xD;
         20. In the opinion of the Investigator, any disease processes or confounding variables&#xD;
             that would inappropriately alter the outcome of the study.&#xD;
&#xD;
         21. Inability to comply with the requirements of the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ayla Rasmussen</last_name>
    <phone>443-569-9228</phone>
    <email>arasmussen@renibus.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Heart Center Research, LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Benton Washburn, MD</last_name>
    </contact>
    <investigator>
      <last_name>T Benton Washburn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Cottage Hospital</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominic Tedesco, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dominic Tedesco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lutheran Medical Group</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Scavo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vincent Scavo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute, Inc.</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Abeel Mangi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arman Arghami, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arman Arghami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rochester General Hospital Center for Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Corteville, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Corteville, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jessen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Jessen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gold Cost University Hospital &amp; Health Services</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvio Provenzano, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sylvio Provenzano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Smith, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Julian Smith, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayme Bennetts, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jayme Bennetts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvano Marasco, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Silvano Marasco, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St-John Regional Hospital</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Brown, MD</last_name>
    </contact>
    <investigator>
      <last_name>Craig Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Lamy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andre Lamy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

